Clipmarks
   
  
   
sowganyafollowshare
9-23-2007 2:43 AM
148 views
sowganya says:
Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of insomnia agents selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA-A receptors.
Login to Comment.  Not a member yet? Sign up
Embed This Clip In Your Site...

New from the makers of Clipmarks:  Amplify.com - Don't just share the news...Amplify it!

OK